Flavopiridol | L86-8275 | CDK Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / Flavopiridol

夫拉平度 /Flavopiridol {[allProObj[0].p_purity_real_show]}

货号：A172904 同义名： L86-8275;Alvocidib

Flavopiridol (Alvocidib)是一种广谱竞争性CDK抑制剂，靶向CDK1、CDK2和CDK4，IC50值分别为30 nM、170 nM和100 nM。

Flavopiridol 化学结构
CAS号：146426-40-6

Flavopiridol 3D分子结构
CAS号：146426-40-6

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Flavopiridol 纯度/质量文件产品仅供科研

货号：A172904 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JMC, 2024. Ambeed. [ A919389 , A918471 , A995972 ]; • Anal. Chem., 2024, 96(50): 19947-19954. Ambeed. [ A261947 , A1165388 ]; • ACS Biomater. Sci. Eng., 2024. Ambeed. [ A220462 ]; • ACS Biomater. Sci. Eng., 2024. Ambeed. [ A165235 , A110205 ]; • Pharmaceutics, 2024, 16(12): 1546. Ambeed. [ A272538 , A187261 , A691302 , A506702 ]; 更多 >

自噬亚型比较
CDK 亚型比较

产品名称	Autophagy ↓ ↑	其他靶点	纯度
SBI-0206965	+++ ULK1, IC50: 108 nM ULK2, IC50: 711 nM		97%
Hydroxychloroquine sulfate	✔		99%
Valproic acid sodium	✔	HDAC	97%
PFK-015	++ PFKFB3, IC50: 207 nM		99%+
MRT68921 hydrochloride	++++ ULK1, IC50: 2.9 nM ULK2, IC50: 1.1 nM		99%+
ROC-325	✔		99%+
Autophinib	+++ Autophagy, IC50: 40 nM		99%
Lys05	✔		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	Cdc ↓ ↑	CDK1 ↓ ↑	CDK19 ↓ ↑	CDK2 ↓ ↑	CDK3 ↓ ↑	CDK4 ↓ ↑	CDK5 ↓ ↑	CDK6 ↓ ↑	CDK7 ↓ ↑	CDK8 ↓ ↑	CDK9 ↓ ↑	CLK ↓ ↑	其他靶点	纯度
XL413 hydrochloride	++++ Cdc7, IC50: 3.4 nM													99%+
SU9516		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 22 nM		++ CDK4, IC50: 200 nM								99%+
RO-3306		+++ CDK1, Ki: 20 nM											ERK,SGK	98%
R547		++++ CDK1/CyclinB, Ki: 2 nM		++++ CDK2/CyclinE, Ki: 3 nM		++++ CDK4/CyclinD1, Ki: 1 nM								99%+
BMS-265246		++++ CDK1/CyclinB, IC50: 6 nM		++++ CDK2/CyclinE, IC50: 9 nM		+ CDK4/CyclinD, IC50: 230 nM								99%+
NU6027		+ CDK1, Ki: 2.5 μM		+ CDK2, Ki: 1.3 μM									DNA-PK	98%
Purvalanol A	++++ Cdc2/CyclinB, IC50: 4 nM			+++ CDK2/CyclinE, IC50: 35 nM CDK2/CyclinA, IC50: 70 nM		+ CDK4/CyclinD1, IC50: 850 nM								99%+
SCH900776				++ CDK2, IC50: 0.16 μM										99%+
AUZ 454				++++ CDK2(C118L), Kd: 18.6 nM CDK2(A144C), Kd: 9.7 nM										99%+
A-674563 HCl				++ CDK2, Ki: 46 nM									PKA	99%
JNJ-7706621		++++ CDK1/CyclinB, IC50: 9 nM		++++ CDK2/CyclinE, IC50: 3 nM CDK2/CyclinA, IC50: 4 nM	++ CDK3/CyclinE, IC50: 58 nM	+ CDK4/CyclinD1, IC50: 253 nM		++ CDK6/CyclinD1, IC50: 175 nM						99%+
AT7519		++ CDK1/CyclinB, IC50: 210 nM		++ CDK2/CyclinA, IC50: 47 nM	+ CDK3/CyclinE, IC50: 360 nM	++ CDK4/CyclinD1, IC50: 100 nM	+++ CDK5/p35, IC50: 13 nM	++ CDK6/CyclinD3, IC50: 170 nM			++++ CDK9/CyclinT, IC50: <10 nM			98+%
PHA-793887		++ CDK1/CyclinB, IC50: 60 nM		++++ CDK2/CyclinE, IC50: 8 nM CDK2/CyclinA, IC50: 8 nM		++ CDK4/CyclinD1, IC50: 62 nM	++++ CDK5/p25, IC50: 5 nM		++++ CDK7/CyclinH, IC50: 10 nM		++ CDK9/CyclinT1, IC50: 138 nM			99%+
Milciclib		+ CDK1/CyclinB, IC50: 398 nM		++ CDK2/CyclinE, IC50: 363 nM CDK2/CyclinA, IC50: 45 nM		++ CDK4/CyclinD1, IC50: 160 nM	+ CDK5/p35, IC50: 265 nM		++ CDK7/CyclinH, IC50: 150 nM					99%+
Kenpaullone		+ CDK1/CyclinB, IC50: 0.4μM		+ CDK2/CyclinE, IC50: 7.5μM CDK2/CyclinA, IC50: 0.68μM			+ CDK5/p35, IC50: 0.85μM							98%
SNS-032				+++ CDK2/CyclinE, IC50: 48 nM CDK2/CyclinA, IC50: 38 nM			+ CDK5/p35, IC50: 340 nM		++ CDK7/CyclinH, IC50: 62 nM		++++ CDK9/CyclinT, IC50: 4 nM			99%+
Dinaciclib		++++ CDK1, IC50: 3 nM		++++ CDK2, IC50: 1 nM			++++ CDK5, IC50: 1 nM				++++ CDK9, IC50: 4 nM			99%+
PHA-767491 hydrochloride	++++ Cdc7, IC50: 10 nM	+ CDK1, IC50: 250 nM		+ CDK2, IC50: 240 nM			+ CDK5, IC50: 460 nM				+++ CDK9, IC50: 34 nM		MK2	99%
(R)-Roscovitine	+ Cdc2/CyclinB, IC50: 0.65 μM			+ CDK2/CyclinE, IC50: 0.7 μM CDK2/CyclinA, IC50: 0.7 μM			++ CDK5/p35, IC50: 0.16 μM							99%+
Narazaciclib						++++ CDK4/CyclinD1, IC50: 3.87 nM		++++ CDK6/CyclinD1, IC50: 9.82 nM					RET	99%+
Palbociclib						++++ CDK4/CyclinD1, IC50: 11 nM CDK4/CyclinD3, IC50: 9 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%
Abemaciclib						++++ CDK4, IC50: 2 nM		++++ CDK6, IC50: 10 nM						99%
Ribociclib						++++ CDK4, IC50: 10 nM		+++ CDK6, IC50: 39 nM						98%
Palbociclib isethionate						++++ CDK4/CyclinD1, IC50: 11 nM CDK4/CyclinD3, IC50: 9 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%+
BS-181 HCl									+++ CDK7, IC50: 21 nM					99%+
(E/Z)-THZ1 dihydrochloride									++++ CDK7, IC50: 3.2 nM					99%+
LDC4297									++++ CDK7, IC50: 0.13 nM					99%+
Senexin A			+ CDK19, Kd: 0.31 μM							+ CDK8, Kd: 0.83 μM				99%
MSC2530818										++++ CDK8, IC50: 2.6 nM				99%+
Wogonin											✔			99%+
Riviciclib HCl		++ CDK1/CyclinB, IC50: 79 nM		+ CDK2/CyclinE, IC50: 2.54 μM CDK2/CyclinA, IC50: 224 nM		++ CDK4/CyclinD1, IC50: 63 nM		+ CDK6/CyclinD3, IC50: 396 nM	+ CDK7/CyclinH, IC50: 2.87 μM		+++ CDK9/CyclinT1, IC50: 20 nM			99+%
LDC000067				+ CDK2, IC50: 2.441 μM							++ CDK9, IC50: 44 nM			98%
Flavopiridol		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 40 nM		+++ CDK4, IC50: 40 nM		+++ CDK6, IC50: 40 nM	+ CDK7, IC50: 300 nM		+++ CDK9, IC50: 20 nM			99%+
LY2857785									+ CDK7, IC50: 0.246 μM	+++ CDK8, IC50: 0.016 μM	+++ CDK9, IC50: 0.011 μM			99%+
AZD-5438		+++ CDK1, IC50: 16 nM		++++ CDK2, IC50: 6 nM							+++ CDK9, IC50: 20 nM			99%+
ML167												++ CLK4, IC50: 136 nM Dyrk1B , IC50: 1648 nM		99%+
(E/Z)-TG003												+++ mCLK1, IC50: 200 nM mCLK4, IC50: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Flavopiridol 生物活性

靶点	CDK4 CDK4, IC50:20-40 nM CDK2 CDK2, IC50:40 nM CDK6 CDK6, IC50:60 nM CDK9 CDK9, IC50:20 nM
描述	Flavopiridol is a pan CDK inhibitor with IC50 value of 30nM, 40nM, 20-40nM, 60nM, 875nM and 20nM for CDK1, 2, 4, 6, 7, 9 (measured by in vitro kinase assays), respectively^[1]^[2]. It can inhibit the whole cell cycle progression through a variety of mechanisms related to CDK inactivation including: 1. Inhibition of CDK4/6 with cyclin D leads to decreased level of pRb-p107 and p130, as well as inactivation of E2F and stop in G1 progression; 2. Inhibition of cdk2 accompanied with cyclin A or E leads to further decreased phosphorylation and inactivation of Rb, as well as inactivation of E2F, and results in retardation in cell cycle progression through the S-phase and accumulation in G1 and G2; 3. Inhibition of CDK1 accompanied with cyclin A or B leads to inhibition of activation of topoisomerase activators, of lamin proteoglycans histone 1 protein and chromatin condensation, as well as results in retardation in cell cycle progression through S-phase and accumulation in G2 phase; 4. Inhibition of cdk7 accompanied with cyclin H complexes leads to reduced activation of cdk’s, such as CDK4 with cyclin D or CDK1 with cyclin B, and reduced activation of RNA polymerase; 5. Flavopiridol may directly influence expression of cyclin D1 and D3 or participate directly in the control of transcription and activation of RNA-polymerase. Flavopiridol is able to induce apoptosis of tumor cells, including leukemia cells, head and neck tumors, breast carcinomas and non-small cell lung carcinoma cell lines, as well as normal cells in vitro after 6–48h with concentration ranging in 0.1–0.4uM^[3]. Intraperitoneal treatment of 5mg/kg flavopiridol for 12 days showed antitumor activity in subcutaneous HN12 xenograft mice^[4]. Clinical studies of flavopiridol of treatement for advanced solid tumors, ALL, AML, CLL, CML, mantle cell lymphoma, multiple myeloma, non-Hodgkin and other lymphomas, advanced sarcomas, breast, esophageal, head and neck, kidney, ovarian, pancreatic, gastric carcinomas and NSCLC are undergoing^[5].
作用机制	Flavopiridol is an ATP-competitive inhibitor^[6].

Flavopiridol 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
A2780 cell		Function assay		Inhibition of A2780 cell clonogenic assay， IC50=15 μM	11063609
A2780/DDP-R human ovarian carcinoma cell		Proliferation assay		Inhibition of A2780/DDP-R human ovarian carcinoma cell proliferation, IC50=38 nM	12190313
A2780/DDP-S human ovarian carcinoma cell		Proliferation assay		Inhibition of A2780/DDP-S human ovarian carcinoma cell proliferation, IC50=56 nM	12190313
A2780/TAX-R human ovarian carcinoma cell		Proliferation assay		Inhibition of A2780/TAX-R human ovarian carcinoma cell proliferation, IC50=78 nM	12190313

Flavopiridol 动物研究

Dose

Mice: min = 5 mg/kg, max = 7.5 mg/kg[6]

Administration

i.p.

Pharmacokinetics

Animal	Mice
AUC_0→∞	1.6 h (i.p.)

Flavopiridol 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03604783	Advanced Solid Tumors	Phase 1	Not yet recruiting	May 2021	United States, Wisconsin ... 展开 >> Medical College of Wisconsin Not yet recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Katy C Schroeder, BSN, RN, OCN 414-805-8843 Principal Investigator: Ben George, MD 收起 <<
NCT00055380	Cancer	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 收起 <<
NCT00003004	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<

Flavopiridol 参考文献

[1]Montagnoli A, Valsasina B, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008 Jun;4(6):357-65.

[2]Aleem E, Arceci RJ, et al. Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol. 2015 Apr 9;3:16.

[3]Sedlacek HH, et al. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol. 2001 May;38(2):139-70.

[4]Roskoski R Jr, et al. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol Res. 2016 May;107:249-275.

[5]Li Y, Zhang J, et al. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2. Int J Mol Sci. 2015 Apr 24;16(5):9314-40.

Flavopiridol 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.49mL

0.50mL

0.25mL

12.44mL

2.49mL

1.24mL

24.89mL

4.98mL

2.49mL

Flavopiridol 技术信息

CAS号	146426-40-6
分子式	C₂₁H₂₀ClNO₅
分子量	401.84

别名	L86-8275;Alvocidib;HL 275;NSC 649890;HMR-1275
运输	蓝冰

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry,2-8°C

溶解度

DMSO: 35 mg/mL(87.1 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03604783	Advanced Solid Tumors	Phase 1	Not yet recruiting	May 2021	United States, Wisconsin ... 展开 >> Medical College of Wisconsin Not yet recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Katy C Schroeder, BSN, RN, OCN 414-805-8843 Principal Investigator: Ben George, MD 收起 <<
NCT00055380	Cancer	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 收起 <<
NCT00003004	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00634244	Adult Acute Megakaryoblastic L... 展开 >>eukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Recurrent Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Arizona Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Iowa Siouxland Hematology Oncology Associates Sioux City, Iowa, United States, 51101 United States, Maryland Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Tufts Medical Center Boston, Massachusetts, United States, 02111 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Ohio The Jewish Hospital Cincinnati, Ohio, United States, 45236 United States, Pennsylvania Geisinger Medical Center Danville, Pennsylvania, United States, 17822-2001 Geisinger Medical Center-Cancer Center Hazleton Hazleton, Pennsylvania, United States, 18201 Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 Lewistown Hospital Lewistown, Pennsylvania, United States, 17044 Geisinger Medical Group State College, Pennsylvania, United States, 16801 Mount Nittany Medical Center State College, Pennsylvania, United States, 16803 Geisinger Wyoming Valley Wilkes-Barre, Pennsylvania, United States, 18711 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Israel Rambam Medical Center Haifa, Israel, 31096 收起 <<
NCT00042874	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00634244	-		Completed	-	-
NCT00040729	-		Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 收起 <<
NCT00020332	Breast Cancer	Phase 1 Phase 2	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 收起 <<
NCT00021073	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT02520011	Acute Myeloid Leukemia	Phase 2	Recruiting	December 2019	-
NCT00046917	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00020189	Head and Neck Cancer ... 展开 >> Thromboembolism 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Center for Cancer Research Bethesda, Maryland, United States, 20892 收起 <<
NCT00003690	Breast Cancer ... 展开 >> Melanoma (Skin) Prostate Cancer Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00006245	Esophageal Cancer	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00795002	Acute Myeloid Leukemia With Mu... 展开 >>ltilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Washington Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
NCT00016185	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Michigan ... 展开 >> Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201-1379 收起 <<
NCT00058227	B-cell Chronic Lymphocytic Leu... 展开 >>kemia Contiguous Stage II Grade 1 Follicular Lymphoma Contiguous Stage II Grade 2 Follicular Lymphoma Contiguous Stage II Mantle Cell Lymphoma Contiguous Stage II Marginal Zone Lymphoma Contiguous Stage II Small Lymphocytic Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Noncontiguous Stage II Grade 1 Follicular Lymphoma Noncontiguous Stage II Grade 2 Follicular Lymphoma Noncontiguous Stage II Mantle Cell Lymphoma Noncontiguous Stage II Marginal Zone Lymphoma Noncontiguous Stage II Small Lymphocytic Lymphoma Progressive Hairy Cell Leukemia, Initial Treatment Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Hairy Cell Leukemia Splenic Marginal Zone Lymphoma Stage I Chronic Lymphocytic Leukemia Stage I Grade 1 Follicular Lymphoma Stage I Grade 2 Follicular Lymphoma Stage I Mantle Cell Lymphoma Stage I Marginal Zone Lymphoma Stage I Small Lymphocytic Lymphoma Stage II Chronic Lymphocytic Leukemia Stage III Chronic Lymphocytic Leukemia Stage III Grade 1 Follicular Lymphoma Stage III Grade 2 Follicular Lymphoma Stage III Mantle Cell Lymphoma Stage III Marginal Zone Lymphoma Stage III Small Lymphocytic Lymphoma Stage IV Chronic Lymphocytic Leukemia Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Small Lymphocytic Lymphoma Untreated Hairy Cell Leukemia Waldenström Macroglobulinemia 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT00006485	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00045448	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00072436	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00087282	Liver Cancer	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00957905	Recurrent Extragonadal Seminom... 展开 >>a Recurrent Malignant Extragonadal Germ Cell Tumor Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor Recurrent Malignant Testicular Germ Cell Tumor Recurrent Ovarian Germ Cell Tumor Stage III Testicular Cancer Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor Stage IV Extragonadal Seminoma Stage IV Ovarian Germ Cell Tumor 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Tower Cancer Research Foundation Beverly Hills, California, United States, 90211-1850 City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania UPMC-Presbyterian Hospital Pittsburgh, Pennsylvania, United States, 15213 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Wisconsin Riverview Hospital Wisconsin Rapids, Wisconsin, United States, 54494 收起 <<
NCT00957905	-		Completed	-	-
NCT00064285	Leukemia	Phase 1	Completed	-	United States, Maryland ... 展开 >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 United States, Ohio Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University Cleveland, Ohio, United States, 44106-5047 United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-4283 United States, Virginia Massey Cancer Center at Virginia Commonwealth University Richmond, Virginia, United States, 23298 收起 <<
NCT01349972	Acute Myeloid Leukemia With Mu... 展开 >>ltilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic Scottsdale-Phoenix Scottsdale, Arizona, United States, 85259 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Blood and Marrow Transplant Group of Georgia Atlanta, Georgia, United States, 30342 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas Baylor University Medical Center Dallas, Texas, United States, 75246 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 收起 <<
NCT00795002	-		Completed	-	-
NCT00005074	Lymphoma	Phase 2	Completed	-	Canada, Nova Scotia ... 展开 >> Nova Scotia Cancer Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Cancer Care Ontario-Hamilton Regional Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Toronto General Hospital Toronto, Ontario, Canada, M5G 2C4 Humber River Regional Hospital Weston, Ontario, Canada, M9N 1N8 收起 <<
NCT01349972	-		Completed	-	-
NCT00023894	Endometrial Cancer	Phase 2	Completed	-	-
NCT03593915	Myelodysplastic Syndromes (MDS... 展开 >>) 收起 <<	Phase 1 Phase 2	Recruiting	May 2022	United States, Maryland ... 展开 >> Johns Hopkins Not yet recruiting Baltimore, Maryland, United States, 21218 Contact: Amy DeZern, MD Principal Investigator: Amy DeZern, MD United States, Texas US Oncology - Texas Oncology - Austin Midtown Recruiting Austin, Texas, United States, 78705 Contact: Jason Melear, MD 512-421-4163 Principal Investigator: Jason Melear, MD US Oncology - Texas Oncology - San Antonio Medical Center Recruiting San Antonio, Texas, United States, 78240 Contact: Roger Lyons, MD Principal Investigator: Roger Lyons, MD US Oncology - Texas Oncology - Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Habte Yimer, MD 903-579-9800 Principal Investigator: Habte Yimer, MD United States, Washington US Oncology - Northwest Cancer Specialists, P.C. Recruiting Vancouver, Washington, United States, 98684 Contact: David A Smith, MD Principal Investigator: David A Smith, MD 收起 <<
NCT00094978	Carcinoma, Small Cell ... 展开 >> Carcinoma, Non-Small-Cell Lung Esophageal Neoplasms Mesothelioma 收起 <<	Phase 1	Terminated	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00005971	Melanoma (Skin)	Phase 2	Completed	-	-
NCT00016939	Kidney Cancer	Phase 2	Completed	-	-
NCT00019344	Lymphoma Pros... 展开 >>tate Cancer Small Intestine Cancer Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Medicine Branch Bethesda, Maryland, United States, 20892 收起 <<
NCT00407966	Adult Acute Basophilic Leukemi... 展开 >>a Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 收起 <<
NCT01076556	Chronic Lymphocytic Leukemia ... 展开 >> Prolymphocytic Leukemia Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Stage I Chronic Lymphocytic Leukemia Stage I Small Lymphocytic Lymphoma Stage II Chronic Lymphocytic Leukemia Stage II Small Lymphocytic Lymphoma Stage III Chronic Lymphocytic Leukemia Stage III Small Lymphocytic Lymphoma Stage IV Chronic Lymphocytic Leukemia Stage IV Small Lymphocytic Lymphoma 收起 <<	Phase 1	Terminated	-	United States, Ohio ... 展开 >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT00470197	Adult Acute Megakaryoblastic L... 展开 >>eukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Malignant Neoplasm Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT00407966	-		Completed	-	-
NCT03298984	Acute Myeloid Leukemia	Phase 1	Recruiting	October 2019	United States, Maryland ... 展开 >> Johns Hopkins Not yet recruiting Baltimore, Maryland, United States, 21287 Contact: Jackie Greer jgreer6@jhmi.edu Principal Investigator: Douglas Smith, MD United States, New York Columbia University Recruiting New York, New York, United States, 10032 Contact: Sarah Leach sl3971@cumc.columbia.edu Principal Investigator: Daniel Lee, MD United States, North Carolina University of North Carolina Recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Jack Zhang jack_zhang@med.unc.edu Principal Investigator: Joshua Zeidner, MD 收起 <<
NCT03563560	Acute Myeloid Leukemia	Phase 1	Recruiting	October 31, 2019	Japan ... 展开 >> Chugoku Central Hospital Not yet recruiting Fukuyama, Hiroshima, Japan Contact: Chugoku Central Hospital Hokkaido University Hospital Not yet recruiting Sapporo, Hokkaido, Japan Contact: Hokkaido University Hospital University of Tsukuba Hospital Not yet recruiting Tsukuba, Ibaraki, Japan Contact: University of Tsukuba Hospital Tokai University Hospital Recruiting Isehara, Kanagawa, Japan Contact: Tokai University Hospital Osaka City Hospital Organization Not yet recruiting Miyakojima-ku, Osaka, Japan Contact: Osaka City Hospital Organization Kindai University Hospital Not yet recruiting Osakasayama, Osaka, Japan Contact: Kindai University Hospital NTT Medical Center Tokyo Not yet recruiting Shinagawa-ku, Tokyo, Japan Contact: NTT Medical Center Tokyo Kyushu University Hospital Not yet recruiting Fukuoka, Japan Contact: Kyushu University Hospital National Hospital Organization Kyushu Medical Center Not yet recruiting Fukuoka, Japan Contact: National Hospital Organization Kyushu Medical Center Fukushima Medical University Hospital Not yet recruiting Fukushima, Japan Contact: Fukushima Medical University Hospital 收起 <<
NCT00991952	Adenocarcinoma of the Gastroes... 展开 >>ophageal Junction Diffuse Adenocarcinoma of the Stomach Intestinal Adenocarcinoma of the Stomach Mixed Adenocarcinoma of the Stomach Recurrent Gastric Cancer Stage IIIA Gastric Cancer Stage IIIB Gastric Cancer Stage IIIC Gastric Cancer Stage IV Gastric Cancer 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Duarte, California, United States, 91010 UC Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00007917	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00991952	-		Completed	-	-
NCT00082784	Extranodal Marginal Zone Lymph... 展开 >>oma of Mucosa-Associated Lymphoid Tissue Nodal Marginal Zone Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Refractory Plasma Cell Myeloma Splenic Marginal Zone Lymphoma Waldenstrom Macroglobulinemia 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT00070239	Hematopoietic/Lymphoid Cancer ... 展开 >> Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Terminated	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00039455	HER2-positive Breast Cancer ... 展开 >> Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer 收起 <<	Phase 1	Terminated(Administratively co... 展开 >>mplete.) 收起 <<	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00080990	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00003256	Prostate Cancer	Phase 2	Completed	-	United States, California ... 展开 >> Beckman Research Institute, City of Hope Duarte, California, United States, 91010 University of California Davis Cancer Center Sacramento, California, United States, 95817 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Wisconsin University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 收起 <<
NCT00016016	Recurrent Adult Acute Lymphobl... 展开 >>astic Leukemia Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 1 Phase 2	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 收起 <<
NCT00098579	Gastrointestinal Stromal Tumor... 展开 >> Recurrent Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00083122	Recurrent Ovarian Epithelial C... 展开 >>ancer Recurrent Primary Peritoneal Cavity Cancer Stage IIIA Ovarian Epithelial Cancer Stage IIIA Primary Peritoneal Cavity Cancer Stage IIIB Ovarian Epithelial Cancer Stage IIIB Primary Peritoneal Cavity Cancer Stage IIIC Ovarian Epithelial Cancer Stage IIIC Primary Peritoneal Cavity Cancer Stage IV Ovarian Epithelial Cancer Stage IV Primary Peritoneal Cavity Cancer 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00083122	-		Completed	-	-
NCT00112684	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Terminated	-	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT00012181	Recurrent Childhood Brain Stem... 展开 >> Glioma Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Ependymoma Recurrent Childhood Large Cell Lymphoma Recurrent Childhood Liver Cancer Recurrent Childhood Lymphoblastic Lymphoma Recurrent Childhood Malignant Germ Cell Tumor Recurrent Childhood Medulloblastoma Recurrent Childhood Rhabdomyosarcoma Recurrent Childhood Small Noncleaved Cell Lymphoma Recurrent Childhood Soft Tissue Sarcoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recurrent Childhood Visual Pathway and Hypothalamic Glioma Recurrent Childhood Visual Pathway Glioma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Neuroblastoma Recurrent Osteosarcoma Recurrent Retinoblastoma Recurrent Wilms Tumor and Other Childhood Kidney Tumors Recurrent/Refractory Childhood Hodgkin Lymphoma Unspecified Childhood Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> COG Phase I Consortium Arcadia, California, United States, 91006-3776 收起 <<
NCT00324480	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00005974	Sarcoma	Phase 2	Completed	-	-
NCT00735930	Anemia Chroni... 展开 >>c Lymphocytic Leukemia Prolymphocytic Leukemia Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Thrombocytopenia 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT00047307	Adenocarcinoma of the Pancreas... 展开 >> Recurrent Pancreatic Cancer Stage II Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00278330	Blastic Phase Chronic Myelogen... 展开 >>ous Leukemia Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Refractory Anemia With Excess Blasts Relapsing Chronic Myelogenous Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 1	Completed	-	United States, Virginia ... 展开 >> Virginia Commonwealth University Richmond, Virginia, United States, 23298 收起 <<
NCT00331682	-		Completed	-	-
NCT00464633	Leukemia, Lymphocytic, Chronic	Phase 2	Completed	-	-
NCT00047203	Refractory Multiple Myeloma ... 展开 >> Stage I Multiple Myeloma Stage II Multiple Myeloma Stage III Multiple Myeloma 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00003039	Lymphoma	Phase 2	Completed	-	United States, Illinois ... 展开 >> Clinical Sciences Building Chicago, Illinois, United States, 60612 University of Chicago Cancer Research Center Chicago, Illinois, United States, 60637 Louis A. Weiss Memorial Hospital Chicago, Illinois, United States, 60640 Cancer Care Specialists of Central Illinois, S.C. Decatur, Illinois, United States, 62526 Evanston Northwestern Health Care Evanston, Illinois, United States, 60201 Lutheran General Hospital Park Ridge, Illinois, United States, 60068 Oncology/Hematology Associates of Central Illinois, P.C. Peoria, Illinois, United States, 61602 Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 62701 United States, Indiana Fort Wayne Medical Oncology and Hematology, Inc. Fort Wayne, Indiana, United States, 46885-5099 Michiana Hematology/Oncology P.C. South Bend, Indiana, United States, 46617 收起 <<
NCT00079352	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New Mexico ... 展开 >> University of New Mexico Albuquerque, New Mexico, United States, 87106 收起 <<
NCT00003620	B-cell Chronic Lymphocytic Leu... 展开 >>kemia Refractory Chronic Lymphocytic Leukemia Stage I Chronic Lymphocytic Leukemia Stage II Chronic Lymphocytic Leukemia Stage III Chronic Lymphocytic Leukemia Stage IV Chronic Lymphocytic Leukemia 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> Cancer and Leukemia Group B Chicago, Illinois, United States, 60606 收起 <<
NCT00058240	B-cell Chronic Lymphocytic Leu... 展开 >>kemia Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Waldenström Macroglobulinemia 收起 <<	Phase 1 Phase 2	Completed	-	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT00331682	Adenocarcinoma of the Pancreas... 展开 >> Recurrent Pancreatic Cancer Stage IV Pancreatic Cancer 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT03441555	Acute Myeloid Leukemia (AML)	Phase 1	Recruiting	April 21, 2021	United States, California ... 展开 >> USC Norris Cancer Center /ID# 170844 Not yet recruiting Los Angeles, California, United States, 90033 UC Irvine /ID# 201093 Recruiting Orange, California, United States, 92868 UC Davis Comp Cancer Ctr /ID# 170799 Recruiting Sacramento, California, United States, 95817 United States, Florida Sylvester Comprehensive Cancer /ID# 170761 Recruiting Miami, Florida, United States, 33136-1002 United States, Indiana Indiana Blood & Marrow Transpl /ID# 170793 Recruiting Indianapolis, Indiana, United States, 46237 United States, New York NYU Langone Medical Center /ID# 201559 Recruiting New York, New York, United States, 10016-6402 Weill Cornell Medical College /ID# 170800 Not yet recruiting New York, New York, United States, 10021 United States, North Carolina Duke Univ Med Ctr /ID# 170842 Not yet recruiting Durham, North Carolina, United States, 27710 United States, Pennsylvania University of Pittsburgh Medic /ID# 170790 Recruiting Pittsburgh, Pennsylvania, United States, 15261 Germany Universitaetsklinikum Ulm /ID# 203649 Not yet recruiting Ulm, Thueringen, Germany, 89081 Universitaetklinikum Dresden /ID# 168636 Not yet recruiting Dresden, Germany, 01307 Univ Klinik Eppendorf Hamburg /ID# 168633 Not yet recruiting Hamburg, Germany, 20246 United Kingdom University Hospital of Wales /ID# 202302 Not yet recruiting Cardiff, United Kingdom, CF14 4EN Ninewells Hospital /ID# 202304 Recruiting Dundee, United Kingdom, DD1 9SY St. James University Hospital /ID# 202303 Not yet recruiting Leeds, United Kingdom, LS9 7TF 收起 <<
NCT00377104	B-cell Chronic Lymphocytic Leu... 展开 >>kemia Contiguous Stage II Small Lymphocytic Lymphoma Noncontiguous Stage II Small Lymphocytic Lymphoma Stage I Chronic Lymphocytic Leukemia Stage I Small Lymphocytic Lymphoma Stage II Chronic Lymphocytic Leukemia Stage III Chronic Lymphocytic Leukemia Stage III Small Lymphocytic Lymphoma Stage IV Chronic Lymphocytic Leukemia Stage IV Small Lymphocytic Lymphoma 收起 <<	Phase 1	Terminated	-	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT00058240	-		Completed	-	-
NCT00112723	Adult Lymphocyte Depletion Hod... 展开 >>gkin Lymphoma Adult Lymphocyte Predominant Hodgkin Lymphoma Adult Mixed Cellularity Hodgkin Lymphoma Adult Nodular Sclerosis Hodgkin Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Refractory Multiple Myeloma Splenic Marginal Zone Lymphoma Stage I Multiple Myeloma Stage II Multiple Myeloma Stage III Multiple Myeloma Waldenström Macroglobulinemia 收起 <<	Phase 1 Phase 2	Terminated(Administratively Co... 展开 >>mplete) 收起 <<	-	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT00098371	B-cell Chronic Lymphocytic Leu... 展开 >>kemia Prolymphocytic Leukemia Refractory Chronic Lymphocytic Leukemia 收起 <<	Phase 2	Terminated(CTEP Initiated Acti... 展开 >>on.) 收起 <<	-	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT00445341	Lymphoma	Phase 1 Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00098371	-		Terminated(CTEP Initiated Acti... 展开 >>on.) 收起 <<	-	-
NCT00445341	-		Completed	-	-
NCT00101231	Adult Acute Basophilic Leukemi... 展开 >>a Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Relapsing Chronic Myelogenous Leukemia 收起 <<	Phase 1	Terminated	-	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT00112723	-		Terminated(Administratively Co... 展开 >>mplete) 收起 <<	-	-

A2780 cell	Function assay		Inhibition of A2780 cell clonogenic assay， IC50=15 μM	11063609
A2780/DDP-R human ovarian carcinoma cell	Proliferation assay		Inhibition of A2780/DDP-R human ovarian carcinoma cell proliferation, IC50=38 nM	12190313
A2780/DDP-S human ovarian carcinoma cell	Proliferation assay		Inhibition of A2780/DDP-S human ovarian carcinoma cell proliferation, IC50=56 nM	12190313
A2780/TAX-R human ovarian carcinoma cell	Proliferation assay		Inhibition of A2780/TAX-R human ovarian carcinoma cell proliferation, IC50=78 nM	12190313
A2780/TAX-S human ovarian carcinoma cell	Proliferation assay		Inhibition of A2780/TAX-S human ovarian carcinoma cell proliferation, IC50=65 nM	12190313
A431 human squamous cell	Proliferation assay		Inhibition of A431 human squamous cell carcinoma cell proliferation, IC50=75 nM	12190313
A549 human lung carcinoma cell	Proliferation assay		Inhibition of A549 human lung carcinoma cell proliferation, IC50=96 nM	12190313
ABAE human fibroblast cell	Proliferation assay		Inhibition of ABAE human fibroblast cell proliferation, IC50=45 nM	12190313
CACO-2 human colon carcinoma cell	Proliferation assay		Inhibition of CACO-2 human colon carcinoma cell proliferation, IC50=86 nM	12190313
CCRF-CEM human leukemia cell	Proliferation assay		Inhibition of CCRF-CEM human leukemia cell proliferation, IC50=52 nM	12190313
HCT116 cell	Function assay		Inhibition of HCT116 cell clonogenic assay, IC50=13 μM	11063609
HCT116 human colon carcinoma cell	Proliferation assay		Inhibition of HCT116 human colon carcinoma cell proliferation, IC50=18 nM	12190313
HCT116/VM46 human colon carcinoma cell	Proliferation assay		Inhibition of HCT116/VM46 human colon carcinoma cell proliferation, IC50=21 nM	12190313
HCT116/VP35 human colon carcinoma cell	Proliferation assay		Inhibition of HCT116/VP35 human colon carcinoma cell proliferation, IC50=17 nM	12190313
HL60 human leukemia cell	Proliferation assay		Inhibition of HL60 human leukemia cell proliferation, IC50=46 nM	12190313
Hs 27 human fibroblast cell	Proliferation assay		Inhibition of Hs 27 human fibroblast cell proliferation, IC50=51 nM	12190313
human A2780 cell line	Proliferation assay	72 h	Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay, IC50=71 nM	15027863
human A2780 cells	Cytotoxic assay	24 h	Cytotoxicity against human A2780 cells after 24 hrs by MTT assay, GI50=23 nM	23301767
human A2780 cells	Cytotoxic assay	72 h	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay, GI50=29 nM	23301767
human A2780 cells	Cytotoxic assay	48 h	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay, GI50=31 nM	23301767
human A2780 cells	Function assay		Inhibition of cdk-mediated NPM phosphorylation at thr199 in human A2780 cells	18469809
human A2780 cells	Function assay	24 h	Inhibition of cdk-mediated Rb phosphorylation at thr821 in human A2780 cells after 24 hrs	18469809
human HMEC1 cells	Cytotoxic assay	24 h	Cytotoxicity against human HMEC1 cells after 24 hrs by MTT assay, GI50=61 nM	23301767
human HMEC1 cells	Cytotoxic assay	48 h	Cytotoxicity against human HMEC1 cells after 48 hrs by MTT assay, GI50=62 nM	23301767
human HMEC1 cells	Cytotoxic assay	72 h	Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay, GI50=66 nM	23301767
human MRC5 cells	Cytotoxic assay	72 h	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay, GI50=28 nM	23301767
human MRC5 cells	Cytotoxic assay	48 h	Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay, GI50=39 nM	23301767
human MRC5 cells	Cytotoxic assay	24 h	Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay, GI50=49 nM	23301767
human NCI60 cells	Proliferation assay	72 h	Antiproliferative activity against human NCI60 cells after 72 hrs by sulforhodamine B assay, GI50=74.7 nM	21080703
human NCI60 cells	Proliferation assay	72 h	Antiproliferative activity against human NCI60 cells assessed as lethal effect after 72 hrs by sulforhodamine B assay, LC50=0.904 μM	21080703
human ovarian (A2780) cancer cell	Cytotoxic assay		Cytotoxic effect on human ovarian (A2780) cancer cell line, IC50=71 nM	15125971
ID8 cells	Proliferation assay		Antiproliferative activity against ID8 cells, IC50=7 nM	17123821
K562 human leukemia cell	Proliferation assay		Inhibition of K562 human leukemia cell proliferation, IC50=0.13 μM	12190313
LNCaP human prostate carcinoma cell	Proliferation assay		Inhibition of LNCaP human prostate carcinoma cell proliferation	12190313
LS174T human colon carcinoma cell	Proliferation assay		Inhibition of LS174T human colon carcinoma cell proliferation, IC50=65 nM	12190313
LX-1 human lung carcinoma	Proliferation assay		Inhibition of LX-1 human lung carcinoma proliferation, IC50=75 nM	12190313
M109 mouse lung carcinoma cell	Proliferation assay		Inhibition of M109 mouse lung carcinoma cell proliferation, IC50=80 nM	12190313
MCF7 cells	Proliferation assay		Antiproliferative activity against MCF7 cells, IC50=26 nM	17123821
MCF-7 human breast carcinoma cell	Proliferation assay		Inhibition of MCF-7 human breast carcinoma cell proliferation, IC50=66 nM	12190313
MCF-7 tumor cell	Proliferation assay		Inhibition of MCF-7 tumor cell proliferation	10843211
Mia PaCa-2 cell	Function assay		Inhibition of Mia PaCa-2 cell clonogenic assay, IC50=36 μM	11063609
MIP human colon carcinoma cell	Function assay		Inhibition of MIP human colon carcinoma cell line, IC50=0.12 μM	12190313
MLF mouse lung fibroblast cell	Proliferation assay		Inhibition of MLF mouse lung fibroblast cell proliferation, IC50=72 nM	12190313
OVCAR-3 human ovarian carcinoma cell	Proliferation assay		Inhibition of OVCAR-3 human ovarian carcinoma cell proliferation, IC50=54 nM	12190313
PC3 cell	Function assay		Inhibition of PC3 cell clonogenic assay, IC50=10 μM	11063609
PC3 human prostate carcinoma cell	Proliferation assay		Inhibition of PC3 human prostate carcinoma cell proliferation, IC50=66 nM	12190313
Sf9 cells	Function assay		Inhibition of recombinant cyclin A/CDK2 expressed in Sf9 cells, IC50=12 nM	17904366
SKBR-3 human breast carcinoma cell	Proliferation assay		Inhibition of SKBR-3 human breast carcinoma cell proliferation, IC50=77 nM	12190313

夫拉平度 /Flavopiridol {[allProObj[0].p_purity_real_show]}

Flavopiridol 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Flavopiridol 质控信息

Flavopiridol 生物活性

Flavopiridol 细胞研究

Flavopiridol 动物研究

Flavopiridol 临床研究

Flavopiridol 参考文献

Flavopiridol 实验方案

Flavopiridol 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

CDK4	CDK4, IC50:20-40 nM
CDK2	CDK2, IC50:40 nM
CDK6	CDK6, IC50:60 nM
CDK9	CDK9, IC50:20 nM
CDK7	CDK7, IC50:875 nM
CDK1	CDK1, IC50:30 nM
CDK4	CDK4, IC50:40 nM
CDK6	CDK6, IC50:40 nM
CDK7	CDK7, IC50:300 nM
CDK1	CDK1, IC50:40 nM

夫拉平度 /Flavopiridol {[allProObj[0].p_purity_real_show]}

Flavopiridol 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Flavopiridol 质控信息

Flavopiridol 生物活性

Flavopiridol 细胞研究

Flavopiridol 动物研究

Flavopiridol 临床研究

Flavopiridol 参考文献

Flavopiridol 实验方案

Flavopiridol 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Flavopiridol 纯度/质量文件产品仅供科研